Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Endometrial Cancer
•
NCI-CCC Tumor Board Question
•
NCI-CCC Gynecologic Tumor Board Question
•
University of Pennsylvania
What adjuvant therapy do you recommend for comprehensively staged, stage II, FIGO grade 3 deeply invasive endometrial cancer?
Answer from: at Community Practice
I would strongly consider external beam therapy and adjuvant chemotherapy.
Sign in or Register to read more
9480
Related Questions
How do you manage a FIGO stage IB dedifferentiated endometrial carcinoma that is MMR deficient and p53 wt?
Do you perform routine pelvic exams on patients undergoing active treatment for gynecologic cancer without GYN symptoms?
Would you treat with extended field pelvic radiation for a patient with FIGO IIIC1 endometrial cancer who was found with isolated tumor cells (ITCs) on a single paraaortic sentinel lymph node?
Would you add olaparib to maintenance immunotherapy for a patient with recurrent MMR-proficient, HER2-negative serous endometrial carcinoma?
Would you consider trying Pembrolizumab + Lenvatinib after progression on first-line Carboplatin + Paclitaxel + Immunotherapy for metastatic endometrial cancer?
Would you consider the addition of trabectedin to adjuvant doxorubicin in a patient with IVB leiomyosarcoma with completely resected disease (hysterectomy and thigh mass with negative margins)?
Following surgical staging, what adjuvant therapy would you recommend for stage IB grade 3 endometrioid endometrial carcinoma with +LVSI?
Given the negative results of GOG-0238 but the positive results of the RUBY trial, how do you manage isolated vaginal cuff recurrence of endometrial cancer?
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?